The novel oral drug venetoclax can be safely added to standard therapies for some high-risk myeloid blood cancers and in early studies the combination shows promise of improved outcomes, say scientists from Dana-Farber Cancer ...
Dec 6, 2020
0
5
Patients with HER2-positive breast cancer that has started to spread to other parts of the body survive for longer if they are treated with a new drug called pyrotinib, according to results from the longest follow-up of the ...
Nov 8, 2023
0
0
For patients with advanced or metastatic non-small cell lung cancer (NSCLC) and limited performance status, an immune checkpoint inhibitor drug called durvalumab is safe and may benefit overall survival, according to a new ...
Nov 21, 2023
0
37
A pioneering Phase I CAR T cell therapy trial for the treatment of glioblastoma at City of Hope demonstrates promising clinical activity against incurable brain tumors, according to research published in Nature Medicine.
Mar 7, 2024
0
16
Results from the Phase II cohort of the CodeBreaK 100 study showed that treatment with the KRAS G12C inhibitor sotorasib achieved a 37.1% objective response rate and 12.5 months median overall survival in previously treated ...
Jun 4, 2021
0
1
(HealthDay)—For patients with non-small cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1) expression, treatment with atezolizumab results in longer overall survival than chemotherapy, according to a study ...
Oct 1, 2020
0
1
For the first time, researchers have found a potential drug candidate that improved outcomes for patients with a type of childhood brain tumor for which there are no effective treatments. The compound, called ONC201, nearly ...
Aug 16, 2023
0
40
(HealthDay)—For women with recurrent ovarian cancer, overall survival is longer with cytoreductive surgery followed by chemotherapy than with chemotherapy alone, according to a study published in the Dec. 2 issue of the ...
Dec 2, 2021
0
1
For patients with relapsed or refractory multiple myeloma (RRMM), triplet therapy of belantamab mafodotin (belamaf) plus bortezomib and dexamethasone (BVd) improves outcomes, with an acceptable safety profile, according to ...
Feb 10, 2024
0
0
Treatment with trifluridine-tipiracil (FTD-TPI) plus bevacizumab yields longer overall survival than FTD-TPI alone among patients with refractory metastatic colorectal cancer, according to a study published in the May 4 issue ...
May 4, 2023
0
2
